Teva Pharmaceutical Industries has announced that the U.S. Food and Drug Administration (FDA) has approved its interleukin 5 antagonist monoclonal antibody (lgG4 kappa), CINQAIR (reslizumab) Injection. Read More »
UnitedHealthcare celebrated the opening of its new office in Davenport, Iowa last week and the expansion of its headquarters located in West Des Moines. Read More »
Walgreens has confirmed that it will be returning as the second annual Red Nose Day’s exclusive retail partner on May 26. Read More »
UnitedHealthcare Community Plan of Louisiana announced this week that it has awarded more than $3.4 million to 249 physician practices across the state as bonus payments for improving the quality of care for patients who are enrolled in UnitedHealthcare’s Medicaid plans. Read More »
The CVS Health Foundation has released new data from programs that were part of a collaborative effort with the National Association of Free & Charitable Clinics (NAFC) and the National Association of Community Health Centers (NACHC) as part of CVS Health’s multi-year, $5-million commitment to increase nationwide access to health care in communities. Read More »
The Japanese Ministry of Health, Labor and Welfare (MHLW) today approved AstraZeneca's Tagrisso (osimertinib, AZD9291). Read More »
CVS Health has announced that CVS Caremark, its pharmacy benefits manager, has been awarded the Mail Service Pharmacy accreditation by the URAC, a health care accreditation organization located in Washington, D.C. Read More »
Alkermes plc has released data from its schizophrenia portfolio that will be featured at the 5th Biennial Schizophrenia International Research Society (SIRS) Conference that will be held from April 2-6 in Florence Italy. Read More »
Sarepta Therapeutics has announced that its New Drug application (NDA) for eteplirsen will be reviewed by the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System (PCNS) Drug Advisory Committee on April 25. Read More »
Cigna has announced that Cigna Hospital Care, the company’s new group hospital indemnity insurance policy, will be available starting in April. Read More »
Allergan has announced that it has submitted an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for the approval of market Paclitaxel Protein-Bound Particles for Injectable Suspension, 100 mg/vial. Read More »
Meritain Health, an Aetna subsidiary, has announced a collaboration with Banner Health Network (BHN) and Aetna Whole Health, which provides members with access to coordinated care administered by physicians and facilities in accountable care networks nationwide. Read More »
Surescripts has provided new data showing that more than 48,000 providers in New York have turned to technology to help fight prescription fraud and abuse. Read More »
Biota Pharmaceuticals has announced the completed sale of its assets relating to its broad spectrum antibiotic program to a new subsidiary of Spero Therapeutics LLC. Read More »
Discount Drug Mart Inc. recently hosted its biannual pharmacists meeting and promoted a get-out-the vote campaign with funding from the NACDS’ RxIMPACT. Read More »
McKesson announced this week that it has launched its disaster recovery service that will help health care organizations uphold their mission-critical capabilities when disasters strike. Read More »
Walgreens Boots Alliance has announced that it has exercised warrants for the purchase of 22,696,912 common stock shares of AmerisourceBergen Corp. for a total payment of $1.17 billion. Read More »
The American Society of Health-System Pharmacists (ASHP) has published “Extemporaneous Formulations for Pediatric, Geriatric and Special Needs Patients” to aid in the treatment of patients who require medication dosages and forms that are not available commercially. Read More »
Pfizer has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application (MAA) for XELJANZ (tofacitinib citrate) for review. Read More »
The U.S. Food and Drug Administration (FDA) has issued a draft guidance that will help the pharmaceutical industry in its development of approved generic opioid drugs that contain abuse-deterrent formulations (ADF). Read More »
Alerts Sign-up
